tbuckley/cabot-search huggingface dataset:
Gray Matter Hypertrophy and Thickening with Obstructive Sleep Apnea in Middle-aged and Older Adults
Authors: Andrée-Ann Baril, Katia Gagnon, Pauline Brayet, Jacques Montplaisir, Louis De Beaumont, Julie Carrier, Chantal Lafond, Francis L’Heureux, Jean-François Gagnon, Nadia Gosselin
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Obstructive sleep apnea causes intermittent hypoxemia, hemodynamic fluctuations, and sleep fragmentation, all of which could damage cerebral gray matter that can be indirectly assessed by neuroimaging.To investigate whether markers of obstructive sleep apnea severity are associated with gray matter changes among middle-aged and older individuals.Seventy-one subjects (ages, 55-76 yr; apnea-hypopnea index, 0.2-96.6 events/h) were evaluated by magnetic resonance imaging. Two techniques were used: (1) voxel-based morphometry, which measures gray matter volume and concentration; and (2) FreeSurfer (an open source software suite) automated segmentation, which estimates the volume of predefined cortical/subcortical regions and cortical thickness. Regression analyses were performed between gray matter characteristics and markers of obstructive sleep apnea severity (hypoxemia, respiratory disturbances, and sleep fragmentation).Subjects had few symptoms, that is, sleepiness, depression, anxiety, and cognitive deficits. Although no association was found with voxel-based morphometry, FreeSurfer revealed increased gray matter with obstructive sleep apnea. Higher levels of hypoxemia correlated with increased volume and thickness of the left lateral prefrontal cortex as well as increased thickness of the right frontal pole, the right lateral parietal lobules, and the left posterior cingulate cortex. Respiratory disturbances positively correlated with right amygdala volume, and more severe sleep fragmentation was associated with increased thickness of the right inferior frontal gyrus.Gray matter hypertrophy and thickening were associated with hypoxemia, respiratory disturbances, and sleep fragmentation. These structural changes in a group of middle-aged and older individuals may represent adaptive/reactive brain mechanisms attributed to a presymptomatic stage of obstructive sleep apnea.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Authors: John F Seymour, Shuo Ma, Danielle M Brander, Michael Y Choi, Jacqueline Barrientos, Matthew S Davids, Mary Ann Anderson, Anne W Beaven, Steven T Rosen, Constantine S Tam, Betty Prine, Suresh K Agarwal, Wijith Munasinghe, Ming Zhu, L Leanne Lash, Monali Desai, Elisa Cerri, Maria Verdugo, Su Young Kim, Rod A Humerickhouse, Gary B Gordon, Thomas J Kipps, Andrew W Roberts
Journal: The Lancet Oncology (2017)
Predictors of hepatitis B screening among patients with cancer.
Authors: J. Hwang, M. Fisch, H. Zhang, M. A. Kallen, M. Routbort, L. Lal, J. Vierling, M. Suarez-Almazor
Journal: Journal of Clinical Oncology (2011)

180 Background: Patients with hepatitis B virus (HBV) infection are at risk of reactivation after chemotherapy. It is unclear whether all patients or only those with certain risk factors should be screened for HBV before chemotherapy. The purpose of our study was to determine the clinical predictors of HBV screening in a single institution. Methods: In this retrospective, cross-sectional study, we evaluated new patients who received chemotherapy between 1/1/04 and 9/30/07. We collected data on patients' demographics, types of cancer and chemotherapy, and HBV risk factors such as a previous ICD-9 code for hepatitis C or other liver conditions. We searched for HBV screening as defined by an HBsAg or anti-HBc test ordered prior to chemotherapy. In univariate analyses, we examined the association between each of the patient-related variables and HBV screening. We then determined predictors of HBV screening in a multivariable logistic regression model. Results: We found 10,729 patients who had chemotherapy during the study period. Overall, 16.7% had HBV screening. All of the following predictors in the univariate analysis were significant for HBV screening at the p&lt;0.01 level: age, gender, ethnicity, U.S. residence, cancer type, chemotherapy type, and having a HBV risk factor. In multivariable logistic regression examining predictors for screening using HBsAg, we found that Asian ethnicity (OR 1.75; 1.16-2.66), hematologic malignancies (OR 22.65; 19.3-26.31), and the receipt of rituxamab (OR 3.71; 3.03-4.48) were significant predictors at the p&lt;0.01 level. Women were less likely to be screened than men (OR 0.68; 0.59-0.78). We repeated the analyses using the anti-HBc screening test, and the results were similar. Overall, 1.5% of the screened patients had a positive HBV test. Conclusions: We found that ethnicity, cancer types, and chemotherapy drugs predict physician-driven HBV screening. Future research is needed to study the predictors of a positive HBV screening test and reactivation of HBV after chemotherapy. [Table: see text]
Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT).
Authors: Marcos de Lima, Poliana A. Patah, Rima Saliba, Daniel Couriel, Kawah Chan, Laura Worth, Sergio Giralt, Partow Kebriae, Issa Khouri, Laurence Cooper, Marcelo Fernandez-Vina, Pedro Cano, Demetrios Petropoulos, John McMannis, Chitra Hosing, Gabriela Rondon, Krishna V. Komanduri, Richard E. Champlin, Elizabeth J. Shpall
Journal: Blood (2006)
Comparative Pharmacokinetic/Pharmacodynamic Profiles in Japanese and Caucasian Patients with Transfusional Hemosiderosis Receiving Treatment with Deferasirox (Exjade®, ICL670).
Authors: S. Iki, A. Urabe, T. Hata, K. Ohyashiki, S. Nakao, M. Takatoku, T. Ishikawa, J. Kato, Y. Tatsumi, H. Mori, H. Tanii, J. Taniguchi, M. Kondo, H. Schran, B. Rabault
Journal: Blood (2006)
Abstract B48: Prostate cancer pre-treatment with nanoformulated Olaparib overcomes radiation resistance
Authors: Anne L. van de Ven, Shifalika Tangutoori, Paige Baldwin, Ju Qiao, Codi Gharagouzloo, Nina Seitzer, John Clohessy, Houari Korideck, G. Mike Makrigiorgos, Robert Cormack, Pier Paolo Pandolfi, Srinivas Sridhar
Journal: Cancer Research (2017)

Abstract Prostate cancers with PTEN deletions are promising candidates for DNA repair inhibitors such as olaparib and talazoparib. Here we show that radiation-resistant cells and tumors derived from Ptenpc-/-;Trp53pc-/- mice are rendered radiation-sensitive following pre-treatment with liposomal nanoOlaparib. This enhancement in radiosensitivity is accompanied by radiation dose-dependent changes in γ-H2AX expression and is specific to nanoformulated Olaparib alone. In animals, twice-weekly intravenous administration of nanoOlaparib alone results in significant tumor growth inhibition. When nanoOlaparib is administered prior to radiation, we find that a single dose of radiation is sufficient to increase mouse survival time by as much as 10 weeks (study duration = 13 weeks). Using ferumoxytol as a surrogate nanoparticle, magnetic resonance imaging (MRI) studies revealed that nanoOlaparib administration enhances the ability of nanoparticles to accumulate in tumors. Compared to untreated and radiation-only controls, nanoOlaparib-treated tumors showed 18-fold higher nanoparticle accumulation, suggesting that the in vivo efficacy of nanoOlaparib may be potentiated by its ability to enhance its own accumulation in tumors. Citation Format: Anne L. van de Ven, Shifalika Tangutoori, Paige Baldwin, Ju Qiao, Codi Gharagouzloo, Nina Seitzer, John Clohessy, Houari Korideck, G. Mike Makrigiorgos, Robert Cormack, Pier Paolo Pandolfi, Srinivas Sridhar. Prostate cancer pre-treatment with nanoformulated Olaparib overcomes radiation resistance. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B48.
Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy
Authors: James E Talmadge, Elizabeth Reed, Kenneth Cowan, Dmitry Gabrilovich, Phyllis Warkentin, William E. Janssen, James Wisecarver, James Anderson, Mary Mailliard, Sarah Maas, Orhan Turken, Uger Coskun
Journal: Blood (2008)
A joint cross-border investigation of a cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany in 2014 using classic, genotyping and whole genome sequencing methods: lessons learnt
Authors: Lena Fiebig, Thomas A Kohl, Odette Popovici, Margarita Mühlenfeld, Alexander Indra, Daniela Homorodean, Domnica Chiotan, Elvira Richter, Sabine Rüsch-Gerdes, Beatrix Schmidgruber, Patrick Beckert, Barbara Hauer, Stefan Niemann, Franz Allerberger, Walter Haas
Journal: Eurosurveillance (2017)

Molecular surveillance of multidrug-resistant tuberculosis (MDR-TB) using 24-loci MIRU-VNTR in the European Union suggests the occurrence of international transmission. In early 2014, Austria detected a molecular MDR-TB cluster of five isolates. Links to Romania and Germany prompted the three countries to investigate possible cross-border MDR-TB transmission jointly. We searched genotyping databases, genotyped additional isolates from Romania, used whole genome sequencing (WGS) to infer putative transmission links, and investigated pairwise epidemiological links and patient mobility. Ten isolates from 10 patients shared the same 24-loci MIRU-VNTR pattern. Within this cluster, WGS defined two subgroups of four patients each. The first comprised an MDR-TB patient from Romania who had sought medical care in Austria and two patients from Austria. The second comprised patients, two of them epidemiologically linked, who lived in three different countries but had the same city of provenance in Romania. Our findings strongly suggested that the two cases in Austrian citizens resulted from a newly introduced MDR-TB strain, followed by domestic transmission. For the other cases, transmission probably occurred in the same city of provenance. To prevent further MDR-TB transmission, we need to ensure universal access to early and adequate therapy and collaborate closely in tuberculosis care beyond administrative borders.
A Transposon-based Analysis Reveals <i>RASA1</i> Is Involved in Triple-Negative Breast Cancer
Authors: Cristian Suárez-Cabrera, Rita M. Quintana, Ana Bravo, M. Llanos Casanova, Angustias Page, Josefa P. Alameda, Jesús M. Paramio, Alicia Maroto, Javier Salamanca, Adam J. Dupuy, Angel Ramírez, Manuel Navarro
Journal: Cancer Research (2017)

RAS genes are mutated in 20% of human tumors, but these mutations are very rare in breast cancer. Here, we used a mouse model to generate tumors upon activation of a mutagenic T2Onc2 transposon via expression of a transposase driven by the keratin K5 promoter in a p53
TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy
Authors: David Alan Westerman, Giada Zapparoli, Chelsee Hewitt, Kevin Lynch, Linda Mileshkin, Emma Link, Alexander Dobrovic, H. Miles Prince
Journal: Blood (2010)
Correction of Human X-Linked Chronic Granulomatous Disease (X-CGD) Following Transduction of X-CGD CD34+ Cells with a Modified RD114-Pseudotyped Simian Immunodeficiency Virus Lentiviral Vector in a NOD/SCID Mouse Xenograft Model.
Authors: Nora Naumann, Suk See De Ravin, Uimook Choi, Morvarid Moayeri, Yasuhiro Ikeda, Harry L. Malech
Journal: Blood (2006)
A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes.
Authors: Gérard Michel, Dominique Valteau-Couanet, Hélène Esperou, Jean Claude Gentet, François Doz, Françoise Méchinaud, Claire Galambrun, Alain Fischer, Hamadi Zouabi, Christian Puozzo, Gilles Vassal
Journal: Blood (2005)
Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.
Authors: Michael J. Kovacs, Judy-Anne W. Chapman, Lois Shepherd, Ralph Meyer, Michael Keeney, Karen MacKinnon, Keith Stewart, Nancy Paul
Journal: Blood (2005)
SOCS1 and SOCS3 Genes Are Not Methylated In Waldenstrom Macroglobulinemia
Authors: Stephanie Poulain, Rachid Aijjou, Natacha Broucqsault, Salomon Manier, Sylvie Galiégue-Zouitina, Charles Herbaux, Sabine Tricot, Agnes Daudignon, Patrick Duthilleul, Christophe Roumier, Xavier Leleu
Journal: Blood (2010)
170Tm-EDTMP
Authors: Tapas Das, Ajit Shinto, Koramadai Karuppuswamy Kamaleshwaran, Sharmila Banerjee
Journal: Clinical Nuclear Medicine (2017)

We have earlier reported the potential of 170Tm-EDTMP as an alternative cost-effective radiopharmaceutical of 89SrCl2 for bone pain palliation application. Encouraging results obtained in the radiochemical studies and biological evaluations in animal model have prompted us to initiate the clinical study to evaluate the potential of 170Tm-EDTMP in human cancer patients. The serial scintigraphic images represent the whole-body scans of a patient (68 years old woman) with skeletal metastases of carcinoma of the breast origin recorded after administering 370 MBq (10 mCi) of 170Tm-EDTMP at different post-administration time points along with the pre-therapy images recorded with 99mTc-MDP in the same patient.
Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.
Authors: John R. Wingard, Shelly L. Carter, Thomas J. Walsh, Joanne Kurtzberg, Trudy N. Small, Iris D. Gersten, Adam M. Mendizabal, Helen Leather, Dennis L. Confer, Lindsey R. Baden, Richard T. Maziarz, Edward A. Stadtmauer, Javier Bolanos-Meade, Janice Brown, John F. DiPersio, Michael Boeckh, Kieren A. Marr
Journal: Blood (2007)
Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression
Authors: Monika Linke, Ha Thi Thanh Pham, Karl Katholnig, Thomas Schnöller, Anne Miller, Florian Demel, Birgit Schütz, Margit Rosner, Boris Kovacic, Nyamdelger Sukhbaatar, Birgit Niederreiter, Stephan Blüml, Peter Kuess, Veronika Sexl, Mathias Müller, Mario Mikula, Wolfram Weckwerth, Arvand Haschemi, Martin Susani, Markus Hengstschläger, Michael J Gambello, Thomas Weichhart
Journal: Nature Immunology (2017)
IL-12 Stimulates Interferon-Gamma Mediated Inhibition of Tumor-Induced Regulatory T Cell Proliferation and Enhances Tumor Clearance
Authors: Xuefang Cao, Lynne I. Collins, Sheng F. Cai, Joshua C. Mayer, Michael J. Walter, David Piwnica-Worms, Robert D. Schreiber, Timothy J. Ley
Journal: Blood (2008)
Synergistic Antileukemic Interactions Between Valproic Acid and Cytarabine: A Potential Means to Improve the Treatment of Pediatric Acute Myeloid Leukemia.
Authors: Chengzhi Xie, Holly Edwards, Lisa Polin, Hui Zhou, Xuanlin Wang, Song Yang, Salvatore B LoGrasso, Steven Buck, Mark Stout, Jeffrey Rubnitz, Larry Matherly, Jeffrey Taub, Qun Yu, Yubin Ge
Journal: Blood (2009)
Constitutive Expression of Lef-1 in Murine Hematopoietic Progenitors Causes Myeloid and Lymphoid Leukemias Propagated by a Leukemic Stem Cell Population with Lymphoid Characteristics.
Authors: Konstantin Petropoulos, Christina Schessl, Natalia Arseni, Vijay P.S. Rawat, Aniruddha Deshpande, Christiane Stadler, Wolfgang Hiddemann, Leticia Quintanilla-Martinez, Stefan K. Bohlander, Michaela Feuring-Buske, Christian Buske
Journal: Blood (2007)
Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients.
Authors: Susan Branford, Timothy Hughes, John Nicoll, Ron Paquette, Eric Bleickardt, Charles Sawyers, Neil Shah
Journal: Blood (2005)
Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation
Authors: Brett Schrand, Bhavna Verma, Agata Levay, Shradha Patel, Iris Castro, Ana Paula Benaduce, Randall Brenneman, Oliver Umland, Hideo Yagita, Eli Gilboa, Adrian Ishkanian
Journal: Cancer Research (2017)

Abstract Radiotherapy can elicit systemic immune control of local tumors and distant nonirradiated tumor lesions, known as the abscopal effect. Although this effect is enhanced using checkpoint blockade or costimulatory antibodies, objective responses remain suboptimal. As radiotherapy can induce secretion of VEGF and other stress products in the tumor microenvironment, we hypothesized that targeting immunomodulatory drugs to such products will not only reduce toxicity but also broaden the scope of tumor-targeted immunotherapy. Using an oligonucleotide aptamer platform, we show that radiation-induced VEGF-targeted 4-1BB costimulation potentiated both local tumor control and abscopal responses with equal or greater efficiency than 4-1BB, CTLA-4, or PD1 antibodies alone. Although 4-1BB and CTLA-4 antibodies elicited organ-wide inflammatory responses and tissue damage, VEGF-targeted 4-1BB costimulation produced no observable toxicity. These findings suggest that radiation-induced tumor-targeted immunotherapy can improve the therapeutic index and extend the reach of immunomodulatory agents. Cancer Res; 77(6); 1310–21. ©2017 AACR.
Thioredoxin-2 Inhibits Mitochondrial Reactive Oxygen Species Generation and Apoptosis Stress Kinase-1 Activity to Maintain Cardiac Function
Authors: Qunhua Huang, Huanjiao Jenny Zhou, Haifeng Zhang, Yan Huang, Ford Hinojosa-Kirschenbaum, Peidong Fan, Lina Yao, Luiz Belardinelli, George Tellides, Frank J. Giordano, Grant R. Budas, Wang Min
Journal: Circulation (2015)

Background— Thioredoxin 2 (Trx2) is a key mitochondrial protein that regulates cellular redox and survival by suppressing mitochondrial reactive oxygen species generation and by inhibiting apoptosis stress kinase-1 (ASK1)–dependent apoptotic signaling. To date, the role of the mitochondrial Trx2 system in heart failure pathogenesis has not been investigated. Methods and Results— Western blot and histological analysis revealed that Trx2 protein expression levels were reduced in hearts from patients with dilated cardiomyopathy, with a concomitant increase in ASK1 phosphorylation/activity. Cardiac-specific Trx2 knockout mice develop spontaneous dilated cardiomyopathy at 1 month of age with increased heart size, reduced ventricular wall thickness, and a progressive decline in left ventricular contractile function, resulting in mortality due to heart failure by ≈4 months of age. The progressive decline in cardiac function observed in cardiac-specific Trx2 knockout mice was accompanied by the disruption of mitochondrial ultrastructure, mitochondrial membrane depolarization, increased mitochondrial reactive oxygen species generation, and reduced ATP production, correlating with increased ASK1 signaling and increased cardiomyocyte apoptosis. Chronic administration of a highly selective ASK1 inhibitor improved cardiac phenotype and reduced maladaptive left ventricular remodeling with significant reductions in oxidative stress, apoptosis, fibrosis, and cardiac failure. Cellular data from Trx2-deficient cardiomyocytes demonstrated that ASK1 inhibition reduced apoptosis and reduced mitochondrial reactive oxygen species generation. Conclusions— Our data support an essential role for mitochondrial Trx2 in preserving cardiac function by suppressing mitochondrial reactive oxygen species production and ASK1-dependent apoptosis. Inhibition of ASK1 represents a promising therapeutic strategy for the treatment of dilated cardiomyopathy and heart failure.
Incidence and Clinical Course of Immune Reactions after Descemet Membrane Endothelial Keratoplasty
Authors: Deniz Hos, Onur Tuac, Friederike Schaub, Tisha P. Stanzel, Silvia Schrittenlocher, Martin Hellmich, Björn O. Bachmann, Claus Cursiefen
Journal: Ophthalmology (2017)
Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)
Authors: Yasmin H Karimi, Nitin Jain, Margaret Green, Lucy A Godley, Howie Lawrence Weiner, Gregory Malnassy, Noreen Fulton, Andrew Artz, Hongtao Liu, Michael J. Thirman, Michael Daunov, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Journal: Blood (2015)
Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effects of IL-3 in Myeloma,
Authors: Rebecca Silbermann, Marina Bolzoni, Paola Storti, Benedetta Dalla Palma, Sabrina Bonomini, Judy Anderson, G. David Roodman, Nicola Giuliani
Journal: Blood (2011)
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
Authors: M Neuenhahn, J Albrecht, M Odendahl, F Schlott, G Dössinger, M Schiemann, S Lakshmipathi, K Martin, D Bunjes, S Harsdorf, E M Weissinger, H Menzel, M Verbeek, L Uharek, N Kröger, E Wagner, G Kobbe, T Schroeder, M Schmitt, G Held, W Herr, L Germeroth, H Bonig, T Tonn, H Einsele, D H Busch, G U Grigoleit
Journal: Leukemia (2017)
Novel Spliced MLL Fusions Have Been Identified Involving the MLL Partner Genes ELL, EPS15, MLLT3, and SEPT5.
Authors: Claus Meyer, Eric Kowarz, Wajih Brahim, Renate Grümayer, Raouf Ben-Abdelali, Etienne De Braekeleer, Marc De Braekeleer, Elizabeth A. Macintyre, Eric Delabesse, Theo Dingermann, Thomas Klingebiel, Rolf Marschalek
Journal: Blood (2007)
Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC).
Authors: Rachid Baz, Cristina Rodriguez, Rony Abou Jawde, Lisa Rybicki, Matt Kalaycio, Anjali Advani, Ronald Sobecks, Mikkael A. Sekeres
Journal: Blood (2006)
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Vaccination Strategies Determined by Microarray Analysis.
Authors: Maud Condomines, Dirk Hose, Thierry Reme, Michael Hundemer, John De Vos, Marion Baudard, Thomas Moehler, Veronique Pantesco, Jean-Francois Schved, Jean-Francois Rossi, Hartmut Goldschmidt, Bernard Klein
Journal: Blood (2006)
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
Authors: Olga Martinho, Renato Silva-Oliveira, Fernanda P. Cury, Ana Martins Barbosa, Sara Granja, Adriane Feijó Evangelista, Fábio Marques, Vera Miranda-Gonçalves, Diana Cardoso-Carneiro, Flávia E. de Paula, Maicon Zanon, Cristovam Scapulatempo-Neto, Marise A.R. Moreira, Fátima Baltazar, Adhemar Longatto-Filho, Rui Manuel Reis
Journal: Theranostics (2017)

Persistent HPV infection alone is not sufficient for cervical cancer development, which requires additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal disease. In this study, we performed a comprehensive analysis of HER family receptor alterations in cervical adenocarcinoma. We detected overexpression of HER protein, mainly HER2, which was an independent prognostic marker for these patients. By using